Coherus Biosciences announces clinical collaboration with STORM Therapeutics

Coherus BioSciences (CHRS) announced a clinical collaboration with STORM Therapeutics to evaluate STC-15, a METTL3 inhibitor, in combination with LOQTORZI, a next-generation PD-1 inhibitor, in a Phase 1b/2 study for the treatment of non-small cell lung cancer, NSCLC, head and neck squamous cell carcinoma, HNSCC, melanoma and endometrial cancer. “We are excited to partner with STORM on the development of the LOQTORZI/STC-15 combination, with patient dosing underway in the Phase 1b/2 study,” said Theresa LaVallee, Ph.D., Chief Scientific and Development Officer of Coherus. “This collaboration is another example of our strategy for expanding potential LOQTORZI indications beyond NPC through cost-efficient drug supply agreements and evaluating LOQTORZI with novel mechanisms in prioritized tumor types such as NSCLC, HNSCC, and others.”